Maurizio Miglino

Medicine & Life Sciences

1. Acute Myeloid Leukemia 100%
2. fludarabine 96%
3. Cytarabine 61%
4. Myelodysplastic Syndromes 49%
5. Idarubicin 49%
6. Leukemia 48%
7. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 48%
8. Imatinib Mesylate 38%
9. Multiple Myeloma 38%
10. Hodgkin Disease 37%
11. Residual Neoplasm 32%
12. Survival 31%
13. carfilzomib 30%
14. Cytogenetics 29%
15. Myeloid Cells 28%
16. Therapeutics 27%
17. Asparaginase 26%
18. Stem Cells 24%
19. Bone Marrow 24%
20. Daunorubicin 24%
21. Glucosephosphate Dehydrogenase 23%
22. Positron Emission Tomography Computed Tomography 21%
23. Neoplasms 21%
24. Drug Therapy 20%
25. Transplants 20%
26. Salvage Therapy 19%
27. Mutation 19%
28. Genomic Instability 18%
29. B-Cell Chronic Lymphocytic Leukemia 18%
30. Primary Myelofibrosis 18%
31. Cell Death 17%
32. Recurrence 17%
33. Non-Hodgkin's Lymphoma 16%
34. Mitochondria 16%
35. Gemtuzumab 16%
36. Stem Cell Transplantation 15%
37. Hematologic Neoplasms 15%
38. Karyotype 15%
39. Reactive Oxygen Species 15%
40. INCB018424 14%
41. Polymerase Chain Reaction 14%
42. Blood Cells 13%
43. Lymphoma 13%
44. Amino Acids 13%
45. Protein-Tyrosine Kinases 13%
46. DNA Repair 12%
47. Azacitidine 12%
48. Acute Promyelocytic Leukemia 12%
49. Etoposide 12%
50. DNA Damage 12%